An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

MLA

Peter O’Gorman, et al. “An International, Multicenter, Prospective, Observational Study of Neutropenia in Patients Being Treated with Lenalidomide + Dexamethasone for Relapsed or Relapsed/Refractory Multiple Myeloma (RR-MM).” American Journal of Hematology, vol. 91, June 2016, pp. 806–11. EBSCOhost, https://doi.org/10.1002/ajh.24416.

APA

Peter O’Gorman, Diep Gray, Richard Greil, Julian Cooney, Catherine D. Williams, Zsolt Szabo, Evangelos Terpos, Xavier Leleu, Ramón García Sanz, & Jiri Minarik. (2016). An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). American Journal of Hematology, 91, 806–811. https://doi.org/10.1002/ajh.24416

Chicago

Peter O’Gorman, Diep Gray, Richard Greil, Julian Cooney, Catherine D. Williams, Zsolt Szabo, Evangelos Terpos, Xavier Leleu, Ramón García Sanz, and Jiri Minarik. 2016. “An International, Multicenter, Prospective, Observational Study of Neutropenia in Patients Being Treated with Lenalidomide + Dexamethasone for Relapsed or Relapsed/Refractory Multiple Myeloma (RR-MM).” American Journal of Hematology 91 (June): 806–11. doi:10.1002/ajh.24416.